Literature DB >> 18525107

The Eph receptor/ephrin system: an emerging player in the invasion game.

Tessa N Campbell1, Stephen M Robbins.   

Abstract

Eph receptor tyrosine kinases (Ephs) and their membrane-anchored ligands (ephrins) form a vital cell communication system capable of bi-directional signaling. This Eph receptor/ephrin system has classically been demonstrated to play a role in development. However, emerging evidence has revealed differential expression of Ephs and ephrins in numerous cancers. Recent studies suggest that this system influences invasive behaviour, promoting a more aggressive and metastatic phenotype. Hence, this minireview summarizes the current understanding of the contribution of both Eph receptors and their ephrin ligands to invasiveness in cancer, as well as their use as potential therapeutic targets.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18525107

Source DB:  PubMed          Journal:  Curr Issues Mol Biol        ISSN: 1467-3037            Impact factor:   2.081


  21 in total

1.  Ligand-dependent EphB1 signaling suppresses glioma invasion and correlates with patient survival.

Authors:  Lei Teng; Mitsutoshi Nakada; Natsuki Furuyama; Hemragul Sabit; Takuya Furuta; Yutaka Hayashi; Takahisa Takino; Yu Dong; Hiroshi Sato; Yoshimichi Sai; Ken-Ichi Miyamoto; Michael E Berens; Shi-Guang Zhao; Jun-Ichiro Hamada
Journal:  Neuro Oncol       Date:  2013-10-11       Impact factor: 12.300

2.  EphrinB1 expression is dysregulated and promotes oncogenic signaling in medulloblastoma.

Authors:  Nicole McKinney; Liangping Yuan; Hongying Zhang; Jingbo Liu; Yoon-Jae Cho; Elisabeth Rushing; Matthew Schniederjan; Tobey J MacDonald
Journal:  J Neurooncol       Date:  2014-09-26       Impact factor: 4.130

Review 3.  Eph-dependent cell-cell adhesion and segregation in development and cancer.

Authors:  Eva Nievergall; Martin Lackmann; Peter W Janes
Journal:  Cell Mol Life Sci       Date:  2011-12-28       Impact factor: 9.261

4.  Ephrin-B1 reverse signaling controls a posttranscriptional feedback mechanism via miR-124.

Authors:  Dina N Arvanitis; Thomas Jungas; Annie Behar; Alice Davy
Journal:  Mol Cell Biol       Date:  2010-03-22       Impact factor: 4.272

5.  Epigenetic profiling reveals etiologically distinct patterns of DNA methylation in head and neck squamous cell carcinoma.

Authors:  Carmen J Marsit; Brock C Christensen; E Andres Houseman; Margaret R Karagas; Margaret R Wrensch; Ru-Fang Yeh; Heather H Nelson; Joseph L Wiemels; Shichun Zheng; Marshall R Posner; Michael D McClean; John K Wiencke; Karl T Kelsey
Journal:  Carcinogenesis       Date:  2009-01-06       Impact factor: 4.944

Review 6.  Role of IGF1 and EFN-EPH signaling in skeletal metabolism.

Authors:  Richard C Lindsey; Charles H Rundle; Subburaman Mohan
Journal:  J Mol Endocrinol       Date:  2018-03-26       Impact factor: 5.098

7.  Discovery and structural analysis of Eph receptor tyrosine kinase inhibitors.

Authors:  Yongmun Choi; Farisa Syeda; John R Walker; Patrick J Finerty; Dominic Cuerrier; Amy Wojciechowski; Qingsong Liu; Sirano Dhe-Paganon; Nathanael S Gray
Journal:  Bioorg Med Chem Lett       Date:  2009-05-13       Impact factor: 2.823

8.  The phosphorylation of ephrin-B2 ligand promotes glioma cell migration and invasion.

Authors:  Mitsutoshi Nakada; Eric M Anderson; Tim Demuth; Satoko Nakada; Linsey B Reavie; Kelsey L Drake; Dominique B Hoelzinger; Michael E Berens
Journal:  Int J Cancer       Date:  2010-03-01       Impact factor: 7.396

9.  Peritumoral small ephrinA5 isoform level predicts the postoperative survival in hepatocellular carcinoma.

Authors:  Tong-Hong Wang; Kwai-Fong Ng; Ta-Sen Yeh; Yu-Ling Wang; Kung-Hao Liang; Chau-Ting Yeh; Tse-Ching Chen
Journal:  PLoS One       Date:  2012-07-30       Impact factor: 3.240

10.  Mutations of the EPHB6 receptor tyrosine kinase induce a pro-metastatic phenotype in non-small cell lung cancer.

Authors:  Etmar Bulk; Jun Yu; Antje Hascher; Steffen Koschmieder; Rainer Wiewrodt; Utz Krug; Bernd Timmermann; Alessandro Marra; Ludger Hillejan; Karsten Wiebe; Wolfgang E Berdel; Albrecht Schwab; Carsten Müller-Tidow
Journal:  PLoS One       Date:  2012-12-04       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.